FY2029 Earnings Estimate for IPSC Issued By Leerink Partnrs

Century Therapeutics, Inc. (NASDAQ:IPSC) – Leerink Partnrs issued their FY2029 earnings estimates for shares of Century Therapeutics in a note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($1.18) per share for the year. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.63) per share.

IPSC has been the topic of a number of other research reports. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. Chardan Capital dropped their price target on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Piper Sandler lowered their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Century Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Stock Up 0.8 %

NASDAQ:IPSC opened at $0.75 on Friday. The company has a 50-day moving average price of $0.99 and a 200-day moving average price of $1.37. Century Therapeutics has a 12 month low of $0.68 and a 12 month high of $5.51.

Institutional Trading of Century Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in shares of Century Therapeutics by 146.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock worth $1,215,000 after purchasing an additional 714,685 shares during the last quarter. Geode Capital Management LLC boosted its stake in Century Therapeutics by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock valued at $1,002,000 after acquiring an additional 23,413 shares in the last quarter. State Street Corp grew its holdings in Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after purchasing an additional 57,323 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Century Therapeutics during the third quarter worth $284,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Century Therapeutics by 127.5% during the 4th quarter. JPMorgan Chase & Co. now owns 163,189 shares of the company’s stock valued at $165,000 after purchasing an additional 91,468 shares during the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.